While cell therapies have been advancing rapidly, therapies that rely on taking a patient’s own cells, altering them, and reinfusing them back into a patient are costly. Part of the reason why is that the process for doing this is labor intensive. Cellino has developed a platform for producing personalized autologous cell therapies in an automated and scalable fashion. We spoke to Marinna Madrid, co-founder and vice president of product, for Cellino, about the company’s platform technology for cell-based therapies, how it works, and why it may help enable a new era of personalized regenerative therapies.